Smith & Nephew Plc ECC endorsed by Royal College of Surgeons

TIDMSN.

Smith & Nephew Plc

18 April 2018

Smith & Nephew's Expert Connect Centre endorsed by Royal College of Surgeons

18 April 2018

Smith & Nephew (LSE:SN, NYSE:SNN), the global medical technology business, is pleased to announce its state-of-the-art Expert Connect Centre ('ECC') in Watford, UK has become the first commercial surgical training facility in Europe to be accredited by the Royal College of Surgeons.

Widely regarded as the gold standard for accreditation, the Royal College of Surgeons endorsement follows an in-depth assessment of the facilities, resources and portfolio offered at the ECC. The recognition enables delegates to receive Continuing Professional Development (CPD) points when attending Smith & Nephew sessions, demonstrating their commitment to developing their surgical skills.

"Smith & Nephew's Expert Connect Centre offers facilities of the highest quality; its education portfolio is extensive and there was a clear demonstration and a broad confidence in each of the components assessed" said Professor Paul O'Flynn, Quality Assurance and Accreditation, Royal College of Surgeons.

"We're pleased to offer the ECC this accreditation and look forward to continue seeing the centre enable surgeons to achieve the highest standards of care."

"This endorsement from the Royal College of Surgeons is a huge honour and recognition of the quality of our medical training and education. We're very proud to be regarded as a benchmark professional development facility and look forward to welcoming more healthcare professionals to the Expert Connect Centre as we continue to support them in their vital work improving patients' lives," said Massimiliano Colella, President Europe and Canada, Smith & Nephew.

Since its opening in February 2017, almost 2000 healthcare professionals from the UK and across the globe, including Canada, Japan and China have received training at the ECC. Designed to encourage interaction, the centre offers the same set-up as 14 hospital operating rooms, providing an environment where surgeons and nurses can learn new techniques and refine skills first hand, to ensure the safe and effective use of Smith & Nephew products. It boasts a large auditorium, seating over 80, for plenary sessions and uses the latest broadcasting and recording technology to capture and share the learning experience.

- ends -

Enquiries

 
 Media 
 Charles Reynolds 
  Smith & Nephew     [phone] 
  Matt Copeman 
  Smith & Nephew      [phone] 
 

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 15,000 employees and a presence in more than 100 countries. Annual sales in 2017 were almost $4.8 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).

For more information about Smith & Nephew, please visit our website www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com.

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.

Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAEASLXFSPPEFF

(END) Dow Jones Newswires

April 18, 2018 03:00 ET (07:00 GMT)